Answers are grounded in this paper and cite their sources.
Observational analysis reveals factors impacting outcomes in unrelated allo-HCT recipients, indicating significant implications for care.
Disease- and transplant-related factors strongly influence outcomes after allogeneic hematopoietic cell transplantation (allo-HCT), but sociodemographic and patient-related determinants may also play a key role. We evaluated their impact in unrelated allo-HCT with post-transplant cyclophosphamide (PT-Cy)-based graft-versus-host disease (GVHD) prophylaxis. We performed a retrospective multicenter analysis using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry (P-5891, Shaffer et al.) from 2017–2021. Outcomes included overall survival (OS), relapse, non-relapse mortality (NRM), grade II–IV and III–IV acute GVHD (aGVHD), moderate/severe chronic GVHD (cGVHD), and GVHD-free relapse-free survival (GRFS). Predictors analyzed were recipient age, sex, race/ethnicity, graft source, disease type, disease risk index (DRI), donor age, donor-recipient CMV status, Karnofsky performance status (KPS), and HCT-comorbidity index (HCT-CI). Univariable and multivariable Cox regression were performed; hazard ratios (HR) with 95% confidence intervals (CI) are reported. We included 2,271 unrelated allo-HCT recipients. Mean age was 57.0 (SD 13.9) years, 56.1% were male. Graft source was bone marrow in 90% and peripheral blood in 10%. Primary diagnoses included AML (54%), MDS (29.5%), and ALL (16.5%). Race was Caucasian (87%), African American (4.8%), Asian/other (9%). Myeloablative conditioning was used in 39.8%. KPS was <90 in 44.8%, and HCT-CI was ≥3 in 53%. Median OS was 24 months (IQR 11.6–36). Grade II–IV aGVHD, grade III–IV aGVHD, moderate/severe cGVHD, relapse, and mortality occurred in 29.1%, 6.4%, 11.4%, 27.1%, and 36.9%. On multivariable analysis, predictors of inferior OS included older age [HR 1.01, p=0.003], KPS <90 [HR 1.20, p=0.013], higher HCT-CI [HR 1.11, p<0.001], and high/very high DRI. Lower relapse risk was observed in ALL [HR 0.71, p=0.014], while non-myeloablative conditioning increased relapse [HR 1.43, p=0.004]. Higher NRM was associated with older age [HR 1.03, p<0.001], KPS <90 [HR 1.27, p=0.025], ALL [HR 1.58, p=0.003], and HCT-CI [HR 1.15, p<0.001]. GRFS was worse with Black race [HR 1.38, p=0.016], higher HCT-CI [HR 1.08, p<0.001], older donor age [HR 1.008, p=0.042], reduced-intensity conditioning [HR 1.18, p=0.034], and high/very high DRI. Higher HCT-CI also predicted increased risk of grade III–IV aGVHD [HR 1.12, p=0.003]. Recipient age, KPS, comorbidity burden, disease type, DRI, and conditioning intensity consistently predicted outcomes in unrelated allo-HCT with PT-Cy. Donor age and race also influenced GRFS, while sex, graft source, CMV status, and ethnicity did not.
No takes yet. Share an insight, caveat, or question.
Shahzad et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: